EA200001030A1 - Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов - Google Patents

Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов

Info

Publication number
EA200001030A1
EA200001030A1 EA200001030A EA200001030A EA200001030A1 EA 200001030 A1 EA200001030 A1 EA 200001030A1 EA 200001030 A EA200001030 A EA 200001030A EA 200001030 A EA200001030 A EA 200001030A EA 200001030 A1 EA200001030 A1 EA 200001030A1
Authority
EA
Eurasian Patent Office
Prior art keywords
efavirenz
tablets
hiv
capsules
superdesintegrators
Prior art date
Application number
EA200001030A
Other languages
English (en)
Other versions
EA003217B1 (ru
Inventor
Уилльям Т. Макоой-Морхед
Джон Д. Бюхлер
Брайан Р. Лэндманн
Original Assignee
Дюпон Фармасьютикалз Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200001030(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дюпон Фармасьютикалз Компани filed Critical Дюпон Фармасьютикалз Компани
Publication of EA200001030A1 publication Critical patent/EA200001030A1/ru
Publication of EA003217B1 publication Critical patent/EA003217B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

Данное изобретение предлагает улучшенные пероральные композиции дозированных форм эфавиренза, которые используются для ингибирования вируса иммунного дефицита (HIV; ВИЧ), предупреждения или лечения инфекции ВИЧ и для лечения возникшего в результате синдрома приобретенного иммунодефицита (AIDS; СПИД). В частности, данное изобретение относится к прессованным таблеткам или капсулам, заключающим в себе эфавиренз, которые содержат один или более дезинтеграторов для того, чтобы повысить скорость растворения эфавиренза в желудочно-кишечном тракте, увеличивая таким образом скорость и степень всасывания эфавиренза в организме. Данное изобретение также относится к способу создания таких таблеток или капсул.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001030A 1998-04-07 1999-04-01 Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов EA003217B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (2)

Publication Number Publication Date
EA200001030A1 true EA200001030A1 (ru) 2001-04-23
EA003217B1 EA003217B1 (ru) 2003-02-27

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001030A EA003217B1 (ru) 1998-04-07 1999-04-01 Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов

Country Status (27)

Country Link
US (2) US6238695B1 (ru)
EP (1) EP1067936B1 (ru)
JP (1) JP2002510634A (ru)
KR (1) KR100634253B1 (ru)
CN (1) CN1146419C (ru)
AR (1) AR019031A1 (ru)
AT (1) ATE223719T1 (ru)
AU (1) AU756422B2 (ru)
BR (1) BR9908810A (ru)
CA (1) CA2321523C (ru)
CZ (1) CZ300850B6 (ru)
DE (1) DE69902893T2 (ru)
DK (1) DK1067936T3 (ru)
EA (1) EA003217B1 (ru)
EE (1) EE04391B1 (ru)
ES (1) ES2181417T3 (ru)
HU (1) HU228498B1 (ru)
IL (1) IL138078A (ru)
NO (1) NO325824B1 (ru)
NZ (1) NZ507566A (ru)
PL (1) PL194309B1 (ru)
PT (1) PT1067936E (ru)
SK (1) SK284655B6 (ru)
TW (1) TW576741B (ru)
UA (1) UA72207C2 (ru)
WO (1) WO1999051239A1 (ru)
ZA (1) ZA200004313B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (ru) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2328703C (en) * 1998-06-11 2007-10-30 Pharmacia & Upjohn Company Delavirdine tablet formulation
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
EP1923063A3 (en) * 2003-01-14 2009-04-08 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2006020962A2 (en) 2004-08-13 2006-02-23 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007014393A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
EP2051703B1 (en) * 2005-12-14 2010-07-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
WO2008033487A2 (en) * 2006-09-14 2008-03-20 Chemlink Laboratories Llc Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
MX367937B (es) 2010-01-27 2019-09-12 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.
CN102985072A (zh) * 2010-04-20 2013-03-20 希普拉有限公司 药物组合物
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017029225A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7084587A (en) 1986-04-01 1987-10-20 Upjohn Company, The Methylprednisolone/sodium carboxymethyl starch tablet composition
HU205717B (en) * 1989-04-28 1992-06-29 Daiichi Seiyaku Co Process for producing pharmaceutical composition against human immunodeficiency, comprising pyridionecarboxylic acid derivative
DK0577913T3 (da) * 1992-07-08 1998-01-26 Santen Oy Ophthalmisk præparat indeholdende timolol-hemihydrat
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (ru) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz

Also Published As

Publication number Publication date
CZ300850B6 (cs) 2009-08-26
JP2002510634A (ja) 2002-04-09
EP1067936A1 (en) 2001-01-17
PT1067936E (pt) 2002-12-31
UA72207C2 (ru) 2005-02-15
BR9908810A (pt) 2000-12-19
DE69902893D1 (de) 2002-10-17
KR100634253B1 (ko) 2006-10-16
EE200000589A (et) 2002-04-15
NO20005043L (no) 2000-10-06
CA2321523C (en) 2008-10-07
EP1067936B1 (en) 2002-09-11
NZ507566A (en) 2002-11-26
KR20010042473A (ko) 2001-05-25
DE69902893T2 (de) 2003-04-30
EA003217B1 (ru) 2003-02-27
IL138078A0 (en) 2001-10-31
ZA200004313B (en) 2002-01-30
NO325824B1 (no) 2008-07-21
PL343421A1 (en) 2001-08-13
IL138078A (en) 2005-12-18
WO1999051239A1 (en) 1999-10-14
HUP0101517A3 (en) 2002-11-28
SK14612000A3 (sk) 2001-07-10
HU228498B1 (en) 2013-03-28
ES2181417T3 (es) 2003-02-16
AU3463799A (en) 1999-10-25
TW576741B (en) 2004-02-21
AR019031A1 (es) 2001-12-26
ATE223719T1 (de) 2002-09-15
EE04391B1 (et) 2004-12-15
CN1146419C (zh) 2004-04-21
PL194309B1 (pl) 2007-05-31
HUP0101517A2 (hu) 2001-11-28
US20010012518A1 (en) 2001-08-09
CA2321523A1 (en) 1999-10-14
DK1067936T3 (da) 2003-02-17
AU756422B2 (en) 2003-01-09
NO20005043D0 (no) 2000-10-06
US6555133B2 (en) 2003-04-29
US6238695B1 (en) 2001-05-29
CN1296412A (zh) 2001-05-23
SK284655B6 (sk) 2005-08-04
CZ20003571A3 (cs) 2001-01-17

Similar Documents

Publication Publication Date Title
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
EA199901031A1 (ru) Производные бензимидазола
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
TR200002761T2 (tr) HIV enfeksiyonlarının tedavisi için üç-ikameli 1,3,5-triazin türevleri.
IS7533A (is) Lifrarbólgu C-veirutálmar
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
ATE512976T1 (de) Hemmer des hepatitis-c-virus
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
MY137777A (en) Inhibitors of aspartyl protease
DK1255815T3 (da) Porcint reproduktivt og respiratorisk syndromvirus til fremgangsmåder til anvendelse
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
MA32018B1 (fr) Vaccin
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
DE69430385D1 (de) Hiv-proteaseinhibitoren
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
MY126450A (en) Crystalline efavirenz
DK1053012T3 (da) Farmaceutiske sammensætninger omfattende PEG-asparaginase til behandling af HIV-infektioner
SG152045A1 (en) Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
DK1532279T3 (da) Fremgangsmåde, sammensætning og kit til antigenbinding af Norwalk-lignende vira
WO2002041879A3 (en) Antidiabetic compositions containing a biguanide and a sulfonamide

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU